Ildiko Terebesi

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

Ulrich Lücking, Arne Scholz, Philip Lienau et al. · ChemMedChem · 2017 · 184 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer

Ulrich Lücking, Dirk Kosemund, Niels Böhnke et al. · Journal of Medicinal Chemistry · 2021 · 72 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Discovery of IRAK4 Inhibitors <b>BAY1834845</b> (Zabedosertib) and <b>BAY1830839</b>

Ulrich Bothe, Judith Günther, Reinhard Nubbemeyer et al. · Journal of Medicinal Chemistry · 2024 · 33 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops

Ulrich Luecking, Arne Scholz, Dirk Kosemund et al. · Cancer Research · 2017 · 28 citations

Medicine, Oncology, Pharmacology +16